2-benzyl-2-(1H-2-indenyl)1,2,3,4-tetrahydro-1-naphthalenol | 1296863-13-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 2-benzyl-2-(1H-2-indenyl)1,2,3,4-tetrahydro-1-naphthalenol
• 英文别名: 2-benzyl-2-(1H-inden-2-yl)-3,4-dihydro-1H-naphthalen-1-ol
• CAS: 1296863-13-2
• 化学式: C₂₆H₂₄O
• 分子量: 352.476
• InChiKey: OJQJHFSPUMBXJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (3,4-二氢-1-萘氧基)三甲基硅烷 在 甲醇 、 sodium tetrahydroborate 、 potassium tert-butylate 、 四氯化锡 作用下， 以 乙醚 、 二氯甲烷 、 叔丁醇 为溶剂， 反应 2.0h， 生成 2-benzyl-2-(1H-2-indenyl)1,2,3,4-tetrahydro-1-naphthalenol
  参考文献：
  名称：

  Synthesis of novel mast cell-stabilising and anti-allergic 1,2,3,4-tetrahydro-1-naphthalenols and related compounds

  摘要：

  In a continuation of our studies into indan and tetralin systems as novel modulators of allergic and inflammatory phenomena, we have extended our work to include dimers linked via C-C bonds. Of these compounds, 2-Benzyl-2-[2-phenyl-1-ethenyl]-1,2,3,4-tetrahydro-1-naphthalenol 12 exhibited most promising activity both in vitro and in vivo. (C) 2011 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2011.01.073

文献信息

• COMBINATION THERAPIES FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS
  申请人：The General Hospital Corporation

  公开号：US20210059977A1

  公开（公告）日：2021-03-04

  Described herein are methods of treating neuron inflammation conditions, for example, amyotropic lateral sclerosis and prion disease, comprising administering a therapeutically effective amount of a combination of cromolyn or a cromolyn derivative compound and an anti-inflammatory agent.
• METHODS OF TREATING CYTOKINE RELEASE SYNDROME
  申请人：The General Hospital Corporation

  公开号：US20220218652A1

  公开（公告）日：2022-07-14

  The present disclosure relates to a method of treating at least one Cell-Associated Neurotoxicity Syndrome (ICANS), cancer-related cognitive impairment, Infusion Reaction Syndrome (IRS), Capillary Leak Syndrome (CLS), Tumor Lysis Syndrome (TLS), Macrophage Activation Syndrome (MAS), Systemic Inflammatory Response Syndrome (SIRS), Immune Reconstitution Inflammatory Syndrome (IRIS), Graft-Versus-Host Disease (GVHD), Acute Respiratory Distress Syndrome (ARDS), sepsis, Ebola, avian influenza, smallpox, Systemic Inflammatory Response Syndrome (SIRS), and Immune-related Adverse Events Syndrome (IrAES) in a subject in need thereof, comprising administering a mast cell stabilizer or a compound of Formula I or Formula II: Formula I, Formula II, wherein R 1 is halogen, OH, or —OC(O)C 1-5 alkyl R 2 and R 3 are each independently selected from CO 2 R 4 or CH 2 OR 5 ; R 4 is i L, Na, K, H, C 1-5 alkyl, or —CH 2 CO(C 1-5 alkyl); and R 5 is H or C(O)(C 1-5 alkyl), or a pharmaceutically acceptable salt thereof.